肠易激综合症药物治疗的研究进展

被引：24

作者：

赵靖

郑驰

刘曦

许贲

机构：

[1] 成都军区总医院医务部计划科

来源：

西南军医 | 2012年 / 14卷 / 01期

关键词：

肠易激综合症; 治疗; 进展;

D O I：

暂无

中图分类号：

R574 [肠疾病];

学科分类号：

100201 [内科学];

摘要：

<正>肠易激综合症(Irritable bowel syndrome,IBS)是一种常见的慢性胃肠道疾病,以腹痛、腹部不适和排便习惯改变为主要特征,常持续存在或反复发作,经检查可以排除引起这些症状的器质性疾病,目前认为本病是一种功能性肠道疾病[1]。在西方国家IBS发病率为10%～15%[2],而在中国由于地域,人种不同,各地发病率有所不同,北京地区的发病率为0.82%,广州

引用

页码：134 / 137

页数：4

共 8 条

[1]

Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome [J].

Spiller, Robin C. .

CURRENT OPINION IN PHARMACOLOGY, 2011, 11 (01) :68-74

[2]

Alvimopan Use in Laparoscopic and Open Bowel Resections: Clinical Results in a Large Community Hospital System [J].

Absher, Randall K. ;

Gerkin, Todd M. ;

Banares, Linda W. .

ANNALS OF PHARMACOTHERAPY, 2010, 44 (11) :1701-1708

[3]

Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.[J].Lucinda Harris.International Journal of Women's Health.2010, defa

[4]

Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious Rhesus monkeys [J].

Yogo, Kenji ;

Onoma, Mitsu ;

Ozaki, Ken-ichi ;

Koto, Masao ;

Itoh, Zen ;

Omura, Satoshi ;

Takanashi, Hisanori .

DIGESTIVE DISEASES AND SCIENCES, 2008, 53 (04) :912-918

[5]

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects [J].

Kassinen, Anna ;

Krogius-Kurikka, Lotta ;

Makivuokko, Harri ;

Rinttila, Teemu ;

Paulin, Lars ;

Corander, Jukka ;

Malinen, Erja ;

Apajalahti, Juha ;

Palva, Airi .

GASTROENTEROLOGY, 2007, 133 (01) :24-33

[6]

Lubiprostone - A chloride channel activator [J].

Lacy, Brian E. ;

Levy, L. Campbell .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (04) :345-351

[7]

Functional bowel disorders [J].

Longstreth, George F. ;

Thompson, W. Grant ;

Chey, William D. ;

Houghton, Lesley A. ;

Mearin, Fermin ;

Spiller, Robin C. .

GASTROENTEROLOGY, 2006, 130 (05) :1480-1491

[8]

Guanylin regulatory peptides: structures; biological activities mediated by cyclic GMP and pathobiology.[J].Leonard R Forte.Regulatory Peptides.1999, 1

← 1 →